Cargando…

933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients

BACKGROUND: Cytomegalovirus (CMV) infection is the most common infection after solid organ transplantation. Data on CMV infection in intestinal transplant recipients is limited. METHODS: This is a single-center retrospective cohort study which includes all consecutive intestinal transplant recipient...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Anmary A, Simkins, Jacques, Martin, Eric, Anjan, Shweta, Garcia, Jennifer, O’Brien, Christopher, Vianna, Rodrigo, Natori, Yoichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644333/
http://dx.doi.org/10.1093/ofid/ofab466.1128
_version_ 1784610061479313408
author Fernandez, Anmary A
Simkins, Jacques
Martin, Eric
Anjan, Shweta
Garcia, Jennifer
O’Brien, Christopher
Vianna, Rodrigo
Natori, Yoichiro
author_facet Fernandez, Anmary A
Simkins, Jacques
Martin, Eric
Anjan, Shweta
Garcia, Jennifer
O’Brien, Christopher
Vianna, Rodrigo
Natori, Yoichiro
author_sort Fernandez, Anmary A
collection PubMed
description BACKGROUND: Cytomegalovirus (CMV) infection is the most common infection after solid organ transplantation. Data on CMV infection in intestinal transplant recipients is limited. METHODS: This is a single-center retrospective cohort study which includes all consecutive intestinal transplant recipients who were transplanted between 2009 and 2019. We excluded recipients that showed CMV seronegativity of both donor and recipient. We also excluded those patients who did not have more than 3 months of follow-up. Univariate and multivariate analyses were performed to identify the risk factors for CMV infection. Of note, at our center CMV prophylaxis in intestinal transplant recipients is one year of valganciclovir. RESULTS: A total of 173 recipients were transplanted; 46 recipients were because of CMV serostatus and 32 due to short follow-up. Ninety-five recipients were included finally. The characteristics of our cohort are summarized in Table 1. Of note, the median age was 32 years [range 0-67] and 44 (46.3%) were male. Eighteen (18.9%) recipients needed to stop valganciclovir prophylaxis due to the side effect, especially cytopenia. Twenty-one recipients developed CMV infection including asymptomatic viremia (12/21, 57.1%), CMV syndrome (5/21, 23.8%) and end-organ disease (2 (9.5%) pneumonitis and 2 (9.5%) colitis) at median time of 155 [Interquartile range, IQR 28-254] days from transplant. The median peak viral load and time to negativity were 16000 [IQR 1500-43892] IU/ml and 56 [IQR 49-109] days, respectively. Younger age (p=0.007, Odds ratio 1.03, 95% confidence interval 1.003-1.055) was the independent factor associated with CMV infection. [Image: see text] [Image: see text] CONCLUSION: Despite prolonged prophylaxis, 21 (22.1%) of intestinal transplant recipients developed CMV infection around 5 months post-transplant. This may be because they cannot tolerate valganciclovir prophylaxis and early termination was required. Further strategy should be developed to prevent CMV infection in this vulnerable population. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-8644333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86443332021-12-06 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients Fernandez, Anmary A Simkins, Jacques Martin, Eric Anjan, Shweta Garcia, Jennifer O’Brien, Christopher Vianna, Rodrigo Natori, Yoichiro Open Forum Infect Dis Poster Abstracts BACKGROUND: Cytomegalovirus (CMV) infection is the most common infection after solid organ transplantation. Data on CMV infection in intestinal transplant recipients is limited. METHODS: This is a single-center retrospective cohort study which includes all consecutive intestinal transplant recipients who were transplanted between 2009 and 2019. We excluded recipients that showed CMV seronegativity of both donor and recipient. We also excluded those patients who did not have more than 3 months of follow-up. Univariate and multivariate analyses were performed to identify the risk factors for CMV infection. Of note, at our center CMV prophylaxis in intestinal transplant recipients is one year of valganciclovir. RESULTS: A total of 173 recipients were transplanted; 46 recipients were because of CMV serostatus and 32 due to short follow-up. Ninety-five recipients were included finally. The characteristics of our cohort are summarized in Table 1. Of note, the median age was 32 years [range 0-67] and 44 (46.3%) were male. Eighteen (18.9%) recipients needed to stop valganciclovir prophylaxis due to the side effect, especially cytopenia. Twenty-one recipients developed CMV infection including asymptomatic viremia (12/21, 57.1%), CMV syndrome (5/21, 23.8%) and end-organ disease (2 (9.5%) pneumonitis and 2 (9.5%) colitis) at median time of 155 [Interquartile range, IQR 28-254] days from transplant. The median peak viral load and time to negativity were 16000 [IQR 1500-43892] IU/ml and 56 [IQR 49-109] days, respectively. Younger age (p=0.007, Odds ratio 1.03, 95% confidence interval 1.003-1.055) was the independent factor associated with CMV infection. [Image: see text] [Image: see text] CONCLUSION: Despite prolonged prophylaxis, 21 (22.1%) of intestinal transplant recipients developed CMV infection around 5 months post-transplant. This may be because they cannot tolerate valganciclovir prophylaxis and early termination was required. Further strategy should be developed to prevent CMV infection in this vulnerable population. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2021-12-04 /pmc/articles/PMC8644333/ http://dx.doi.org/10.1093/ofid/ofab466.1128 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Fernandez, Anmary A
Simkins, Jacques
Martin, Eric
Anjan, Shweta
Garcia, Jennifer
O’Brien, Christopher
Vianna, Rodrigo
Natori, Yoichiro
933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title_full 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title_fullStr 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title_full_unstemmed 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title_short 933. Incidence and Risk Factors for Cytomegalovirus Infection in Intestinal Transplant Recipients
title_sort 933. incidence and risk factors for cytomegalovirus infection in intestinal transplant recipients
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644333/
http://dx.doi.org/10.1093/ofid/ofab466.1128
work_keys_str_mv AT fernandezanmarya 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT simkinsjacques 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT martineric 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT anjanshweta 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT garciajennifer 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT obrienchristopher 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT viannarodrigo 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients
AT natoriyoichiro 933incidenceandriskfactorsforcytomegalovirusinfectioninintestinaltransplantrecipients